Seratrodast
[7-Phenyl-7-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)heptanoic
acid] is a thromboxane A2 (TXA2) receptor {TP
receptor} antagonist marketed as an antiasthmatic drug with inhibitory effects
on immediate asthmatic reaction in asthma and airway hypersensitivity. It also
has antagonistic effects on contractile prostanoids, including PGH2,
PGF2α, PGD2, and 11β- PGD2. Thus this drug is
expected to have a wide range of antagonistic effects on bronchoconstriction
mediators [1, 2].
 |
| 2D and 3D Structure for Seratrodast |
Chemically,
it is a quinone derivative with a long alkyl chain ending in a carboxylic acid,
making it poorly soluble in water. It is a chiral molecule, though marketed as
a racemate, studies report the best activities in the following order of
descent: R–enantiomer, racemate and finally S–enantiomer. It is a novel design,
orally active, potent and long acting TP/PGH2 receptor antagonist.
